Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.

Ann Rheum Dis. 2018 Apr 11. pii: annrheumdis-2018-213030. doi: 10.1136/annrheumdis-2018-213030. [Epub ahead of print]

PMID:
29643108
2.

Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.

Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, Gepstein R, Heiligenhaus A, Pilkington CA, Simonini G, Uziel Y, Vastert SJ, Wulffraat NM, Haasnoot AM, Walscheid K, Pálinkás A, Pattani R, Györgyi Z, Kozma R, Boom V, Ponyi A, Ravelli A, Ramanan AV.

Ann Rheum Dis. 2018 Mar 28. pii: annrheumdis-2018-213131. doi: 10.1136/annrheumdis-2018-213131. [Epub ahead of print]

3.

The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey.

Jeyaratnam J, Ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, Dedeoglu F, Baris EH, Vastert SJ, Wulffraat NM, Frenkel J.

Pediatr Rheumatol Online J. 2018 Mar 21;16(1):19. doi: 10.1186/s12969-018-0235-z.

4.

An amino acid motif in HLA-DRβ1 distinguishes patients with uveitis in juvenile idiopathic arthritis.

Haasnoot AJW, Schilham MW, Kamphuis S, Hissink Muller PCE, Heiligenhaus A, Foell D, Minden K, Ophoff RA, Radstake TRDJ, Den Hollander AI, Reinards THCM, Hiddingh S, Schalij-Delfos NE, Hoppenreijs EPAH, van Rossum MAJ, Wouters C, Saurenmann RK, van den Berg JM, Wulffraat NM, Ten Cate R, de Boer JH, Pulit SL, Kuiper JJW.

Arthritis Rheumatol. 2018 Mar 7. doi: 10.1002/art.40484. [Epub ahead of print]

PMID:
29513936
5.

Disease activity and dropout in young persons with juvenile idiopathic arthritis in transition of care: a longitudinal observational study.

van Pelt PA, Dolhain RJEM, Kruize AA, Ammerlaan JJW, Hazes JW, Bijlsma JWJ, Wulffraat NM.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):163-168. Epub 2018 Jan 31.

PMID:
29461957
6.

Patient's experiences with the care for juvenile idiopathic arthritis across Europe.

van Dijkhuizen EHP, Egert T, Egert Y, Costello W, Schoemaker C, Fernhout M, Kepic M, Martini A, Scala S, Rotstein-Grein I, Vastert SJ, Wulffraat NM.

Pediatr Rheumatol Online J. 2018 Feb 8;16(1):10. doi: 10.1186/s12969-018-0226-0.

7.

Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases.

Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, Burman J, Moore J, Rovira M, Wulffraat NM, Kazmi M, Greco R, Snarski E, Kozak T, Kirgizov K, Alexander T, Bader P, Saccardi R, Farge D; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP); EBMT Paediatric Working Party (PWP); Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT); EBMT (JACIE).

Blood Adv. 2017 Dec 20;1(27):2742-2755. doi: 10.1182/bloodadvances.2017010041. eCollection 2017 Dec 26.

8.

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.

Swart JF, van Dijkhuizen EHP, Wulffraat NM, de Roock S.

Ann Rheum Dis. 2018 Mar;77(3):336-342. doi: 10.1136/annrheumdis-2017-212104. Epub 2017 Nov 14.

9.

Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative.

Kuemmerle-Deschner JB, Hansmann S, Wulffraat NM, Vastert SJ, Hens K, Anton J, Avcin T, Martini A, Koné-Paut I, Uziel Y, Ravelli A, Wouters C, Shaw D, Özen S, Eikelberg A, Prakken BJ, Ruperto N, Horneff G, Constantin T, Beresford MW, Sikken M, Foster HE, Haug I, Schuller S, Jägle C, Benseler SM.

Ann Rheum Dis. 2018 Mar;77(3):319-327. doi: 10.1136/annrheumdis-2017-211904. Epub 2017 Oct 11.

PMID:
29021237
10.

European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.

Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Özen S, Pilkington CA, Ravelli A, Royen-Kerkhof AV, Uziel Y, Vastert BJ, Wulffraat NM, Beresford MW, Kamphuis S.

Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.

PMID:
28877866
11.

European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.

Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW.

Ann Rheum Dis. 2017 Oct;76(10):1637-1641. doi: 10.1136/annrheumdis-2016-211001. Epub 2017 May 4. Review.

PMID:
28473426
12.

Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome.

Hoenig M, Lagresle-Peyrou C, Pannicke U, Notarangelo LD, Porta F, Gennery AR, Slatter M, Cowan MJ, Stepensky P, Al-Mousa H, Al-Zahrani D, Pai SY, Al Herz W, Gaspar HB, Veys P, Oshima K, Imai K, Yabe H, Noroski LM, Wulffraat NM, Sykora KW, Soler-Palacin P, Muramatsu H, Al Hilali M, Moshous D, Debatin KM, Schuetz C, Jacobsen EM, Schulz AS, Schwarz K, Fischer A, Friedrich W, Cavazzana M; European Society for Blood and Marrow Transplantation (EBMT) Inborn Errors Working Party.

Blood. 2017 May 25;129(21):2928-2938. doi: 10.1182/blood-2016-11-745638. Epub 2017 Mar 22.

PMID:
28331055
13.

Haematopoietic stem cell transplantation for autoimmune diseases.

Swart JF, Delemarre EM, van Wijk F, Boelens JJ, Kuball J, van Laar JM, Wulffraat NM.

Nat Rev Rheumatol. 2017 Apr;13(4):244-256. doi: 10.1038/nrrheum.2017.7. Epub 2017 Feb 23. Review.

PMID:
28228650
14.

Fatigue in patients with Juvenile Idiopathic Arthritis: relationship to perceived health, physical health, self-efficacy, and participation.

Armbrust W, Lelieveld OH, Tuinstra J, Wulffraat NM, Bos GJ, Cappon J, van Rossum MA, Sauer PJ, Hagedoorn M.

Pediatr Rheumatol Online J. 2016 Dec 6;14(1):65.

15.

Internet Program for Physical Activity and Exercise Capacity in Children With Juvenile Idiopathic Arthritis: A Multicenter Randomized Controlled Trial.

Armbrust W, Bos GJFJ, Wulffraat NM, van Brussel M, Cappon J, Dijkstra PU, Geertzen JHB, Legger GE, van Rossum MAJ, Sauer PJJ, Lelieveld OTHM.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1040-1049. doi: 10.1002/acr.23100. Epub 2017 Jun 9.

PMID:
27696793
16.

Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.

van Dijkhuizen EH, Pouw JN, Scheuern A, Hügle B, Hardt S, Ganser G, Kümmerle-Deschner JB, Horneff G, Holzinger D, Bulatović Ćalasan M, Wulffraat NM.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):148-54. Epub 2016 Feb 2.

PMID:
26843067
17.

Pneumococcal Vaccination Strategies in the Real World of Chronically Ill Patients.

Wulffraat NM, Heijstek MW.

J Rheumatol. 2016 Feb;43(2):255-7. doi: 10.3899/jrheum.151289. No abstract available.

PMID:
26834247
18.

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, Vastert SJ.

Pediatr Rheumatol Online J. 2015 Dec 3;13:55. doi: 10.1186/s12969-015-0055-3. Review.

19.

A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.

Wulffraat NM.

Expert Opin Drug Saf. 2015;14(12):1961-7. doi: 10.1517/14740338.2016.1112377. Epub 2015 Nov 14. Review.

PMID:
26568054
20.

Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells.

Delemarre EM, van den Broek T, Mijnheer G, Meerding J, Wehrens EJ, Olek S, Boes M, van Herwijnen MJ, Broere F, van Royen A, Wulffraat NM, Prakken BJ, Spierings E, van Wijk F.

Blood. 2016 Jan 7;127(1):91-101. doi: 10.1182/blood-2015-06-649145. Epub 2015 Oct 19.

21.

Prevalence of Severe Fatigue Among Adolescents With Pediatric Rheumatic Diseases.

Nijhof LN, van de Putte EM, Wulffraat NM, Nijhof SL.

Arthritis Care Res (Hoboken). 2016 Jan;68(1):108-14. doi: 10.1002/acr.22710.

22.

Recommendations for the management of autoinflammatory diseases.

ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Cantarini L, Galeotti C, Grateau G, Hentgen V, Hofer M, Kallinich T, Kone-Paut I, Lachmann HJ, Ozdogan H, Ozen S, Russo R, Simon A, Uziel Y, Wouters C, Feldman BM, Vastert SJ, Wulffraat NM, Benseler SM, Frenkel J, Gattorno M, Kuemmerle-Deschner JB.

Ann Rheum Dis. 2015 Sep;74(9):1636-44. doi: 10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24. Review.

23.

Vaccinations in paediatric rheumatology: an update on current developments.

Groot N, Heijstek MW, Wulffraat NM.

Curr Rheumatol Rep. 2015 Jul;17(7):46. doi: 10.1007/s11926-015-0519-y. Review.

24.

Use and perceived relevance of health-related Internet sites and online contact with peers among young people with juvenile idiopathic arthritis.

van Pelt PA, Drossaert CH, Kruize AA, Huisman J, Dolhain RJ, Wulffraat NM.

Rheumatology (Oxford). 2015 Oct;54(10):1833-41. doi: 10.1093/rheumatology/kev193. Epub 2015 May 20.

PMID:
25998449
25.

Temporomandibular joint involvement in Juvenile Idiopathic Arthritis: reliability and validity of a screening protocol for the rheumatologist.

Steenks MH, Giancane G, de Leeuw RR, Bronkhorst EM, van Es RJ, Koole R, van Bruggen HW, Wulffraat NM.

Pediatr Rheumatol Online J. 2015 May 7;13:15. doi: 10.1186/s12969-015-0011-2.

26.

Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis.

Bulatović Ćalasan M, Vastert SJ, Scholman RC, Verweij F, Klein M, Wulffraat NM, Prakken BJ, van Wijk F.

Rheumatology (Oxford). 2015 Sep;54(9):1724-34. doi: 10.1093/rheumatology/kev101. Epub 2015 Apr 14.

PMID:
25877908
27.

Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.

Te Boome LC, Mansilla C, van der Wagen LE, Lindemans CA, Petersen EJ, Spierings E, Thus KA, Westinga K, Plantinga M, Bierings M, Broers AE, Cuijpers ML, van Imhoff GW, Janssen JJ, Huisman C, Zeerleder S, Huls G, Boelens JJ, Wulffraat NM, Slaper-Cortenbach IC, Kuball J.

Leukemia. 2015 Sep;29(9):1839-46. doi: 10.1038/leu.2015.89. Epub 2015 Apr 3.

PMID:
25836589
28.

Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.

van Dijkhuizen EH, Bulatović Ćalasan M, Pluijm SM, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM.

Pediatr Rheumatol Online J. 2015 Feb 18;13:5. doi: 10.1186/s12969-015-0002-3. eCollection 2015.

29.

Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.

Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK, Tolar J, Allewelt H, Jones SA, Parini R, Renard M, Bordon V, Wulffraat NM, de Koning TJ, Shapiro EG, Kurtzberg J, Boelens JJ.

Blood. 2015 Mar 26;125(13):2164-72. doi: 10.1182/blood-2014-11-608075. Epub 2015 Jan 26.

30.

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.

van Dijkhuizen EH, Wulffraat NM.

Pediatr Rheumatol Online J. 2014 Dec 11;12:51. doi: 10.1186/1546-0096-12-51. eCollection 2014. Review.

31.

Mesenchymal stromal cells for treatment of arthritis.

Swart JF, Wulffraat NM.

Best Pract Res Clin Rheumatol. 2014 Aug;28(4):589-603. doi: 10.1016/j.berh.2014.10.023. Epub 2014 Oct 30. Review.

PMID:
25481552
32.

Erythrocyte sedimentation rate as baseline predictor for the development of uveitis in children with juvenile idiopathic arthritis.

Haasnoot AJ, van Tent-Hoeve M, Wulffraat NM, Schalij-Delfos NE, Los LI, Armbrust W, Zuithoff NP, de Boer JH.

Am J Ophthalmol. 2015 Feb;159(2):372-7.e1. doi: 10.1016/j.ajo.2014.11.007. Epub 2014 Nov 7.

33.

Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity.

Enders FB, Delemarre EM, Kuemmerle-Deschner J, van der Torre P, Wulffraat NM, Prakken BP, van Royen-Kerkhof A, van Wijk F.

Ann Rheum Dis. 2015 Jan;74(1):315-7. doi: 10.1136/annrheumdis-2014-206287. Epub 2014 Sep 30. No abstract available.

PMID:
25269830
34.

Response to: 'Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis' by Dr Akioka.

Heijstek MW, Wulffraat NM.

Ann Rheum Dis. 2014 Dec;73(12):e76. doi: 10.1136/annrheumdis-2014-206446. Epub 2014 Sep 29. No abstract available.

PMID:
25265936
35.

Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown.

Kalinina Ayuso V, Makhotkina N, van Tent-Hoeve M, de Groot-Mijnes JD, Wulffraat NM, Rothova A, de Boer JH.

Surv Ophthalmol. 2014 Sep-Oct;59(5):517-31. doi: 10.1016/j.survophthal.2014.03.002. Epub 2014 Mar 29. Review.

PMID:
25130893
36.

Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review.

van Dijkhuizen EH, Wulffraat NM.

Ann Rheum Dis. 2015 Nov;74(11):1996-2005. doi: 10.1136/annrheumdis-2014-205265. Epub 2014 Jun 24. Review.

PMID:
24962873
37.

Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.

Ćalasan MB, Wulffraat NM.

Expert Rev Clin Immunol. 2014 Jul;10(7):843-54. doi: 10.1586/1744666X.2014.916617. Epub 2014 May 26. Review.

PMID:
24857620
38.

Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.

Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, Wulffraat NM.

Arthritis Rheumatol. 2014 Apr;66(4):1034-43. doi: 10.1002/art.38296.

39.

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2015 Jul;74(7):1379-86. doi: 10.1136/annrheumdis-2013-204641. Epub 2014 Mar 18.

PMID:
24641940
40.

Brief report: Autologous stem cell transplantation restores immune tolerance in experimental arthritis by renewal and modulation of the Teff cell compartment.

Delemarre EM, Roord ST, van den Broek T, Zonneveld-Huijssoon E, de Jager W, Rozemuller H, Martens AC, Broere F, Wulffraat NM, Glant TT, Prakken BJ, van Wijk F.

Arthritis Rheumatol. 2014 Feb;66(2):350-6. doi: 10.1002/art.38261.

41.

Mesenchymal stem cell therapy in proteoglycan induced arthritis.

Swart JF, de Roock S, Hofhuis FM, Rozemuller H, van den Broek T, Moerer P, Broere F, van Wijk F, Kuis W, Prakken BJ, Martens AC, Wulffraat NM.

Ann Rheum Dis. 2015 Apr;74(4):769-77. doi: 10.1136/annrheumdis-2013-204147. Epub 2014 Jan 6.

PMID:
24395558
42.

Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists.

Armbrust W, Kaak JG, Bouma J, Lelieveld OT, Wulffraat NM, Sauer PJ, van Sonderen E.

Pediatr Rheumatol Online J. 2013 Dec 24;11(1):48. doi: 10.1186/1546-0096-11-48.

43.

Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score.

Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, Pistorio A, Verazza S, Negro G, Gerloni V, Goldenstein-Schainberg C, Sztajnbok F, Wulffraat NM, Martini A, Ravelli A; Paediatric Rheumatology International Trials Organization (PRINTO).

Ann Rheum Dis. 2014 Jul;73(7):1380-3. doi: 10.1136/annrheumdis-2013-204186. Epub 2013 Dec 17.

PMID:
24347571
44.

Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis.

Ćalasan MB, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, Wulffraat NM.

Arthritis Res Ther. 2013;15(6):R217.

45.

Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?

van Royen-Kerkhof A, Vastert BS, Swart JF, Wulffraat NM.

Immunotherapy. 2014;6(1):1-3. doi: 10.2217/imt.13.153. No abstract available.

46.

Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis.

Rothmund F, Gerss J, Ruperto N, Däbritz J, Wittkowski H, Frosch M, Wulffraat NM, Wedderburn LR, Holzinger D, Gohar F, Vastert SJ, Brik R, Deslandre CJ, Melo-Gomes JA, Saad Magalhaes C, Barcellona R, Russo R, Gattorno M, Martini A, Roth J, Foell D; Paediatric Rheumatology International Trials Organisation (PRINTO).

Arthritis Care Res (Hoboken). 2014 Jun;66(6):949-55.

47.

Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis.

de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Ćalasan MB, Weel AE, Huisman AM, Gerards AH, van Schaeybroeck B, Wulffraat NM, Lindemans J, Hazes JM, de Jonge R.

Ann Rheum Dis. 2015 Feb;74(2):408-14. doi: 10.1136/annrheumdis-2013-203725. Epub 2013 Dec 2.

PMID:
24297383
48.

Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients.

Ćalasan MB, den Boer E, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM.

Ann Rheum Dis. 2015 Feb;74(2):402-7. doi: 10.1136/annrheumdis-2013-203723. Epub 2013 Nov 28.

PMID:
24288013
49.

Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis.

Bulatović Calasan M, de Vries LD, Vastert SJ, Heijstek MW, Wulffraat NM.

Rheumatology (Oxford). 2014 Feb;53(2):307-12. doi: 10.1093/rheumatology/ket310. Epub 2013 Oct 24.

PMID:
24162034
50.

Using registries to identify adverse events in rheumatic diseases.

Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.

Pediatrics. 2013 Nov;132(5):e1384-94. doi: 10.1542/peds.2013-0755. Epub 2013 Oct 21. Review.

Supplemental Content

Loading ...
Support Center